---
layout: page
permalink: /public_comments/
title: public comments
description: public comments
nav: false
nav_order: 3
---

### policy and regulatory submissions

- [Reply affidavit on behalf of the petitioner to the statement filed by the senior panel counsel for the 1st respondent.](https://drive.google.com/file/d/1D6mN952TRnNkp6dN1R_ilIcyTIBFCOSn/view?usp=sharing)  Seba PA vs. Union of India and Others. Oct 22 2024

- [Comment on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.](https://files-profile.medicine.yale.edu/documents/674bf175-7547-4c46-a8df-8b2a6d02fcd9) Submitted to Centers for Medicare & Medicaid Services, Department of Health and Human Services. Docket No. CMS-1800-NC3. 2 July 2024.

- [Proposed changes to Bayh-Dole Act: “Rights to Federally Funded Inventions and Licensing of Government Owned Inventions.”](https://drive.google.com/file/d/1gtZw7MIRSuulJ-sKfo0ElP1q0MT80uVu/view?usp=sharing) Submitted to the National Institute of Standards and Technology, Department of Commerce. Docket No. 201207-0327. 6 Feb 2024.

- [Statement for the record for hearing "Why Does the United States Pay, by Far, the Highest Prices in the World for Prescription Drugs?"](https://drive.google.com/file/d/1ipcsDXOVxRKRBDGJkHRzSz3SlGX28W0J/view?usp=sharing). Submitted to the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP). 5 Feb 2024.

  -Clip of Senator Sanders referencing submission and asking pharmaceutical company CEOs about production costs:

  <iframe width="560" height="315" src="https://www.youtube.com/embed/S4-IQfHIbq0?start=2400" frameborder="0" allowfullscreen></iframe>

- [Response to Request for Information on drug shortages.](https://drive.google.com/file/d/19rDDBf6Uet-XCIFG6xEvTmb_2AeTWRZy/view?usp=sharing). Submitted to the House Energy and Commerce Committee. 7 June 2023.
  - See also: [Written testimony for House Energy and Commerce Committee hearing "Legislative Proposals to Prevent and Respond to Generic Drug Shortages"](https://democrats-energycommerce.house.gov/sites/evo-subsites/democrats-energycommerce.house.gov/files/evo-media-document/melissa-barber_witness-testimony_09.14.23.pdf)

- [Review of Risdiplam application for spinal muscular atrophy for the 24th WHO Expert Committee on the Selection and Use of Essential Medicines.](https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/public-comments/a40_risdiplam_barber.pdf?sfvrsn=28a26d21_1) Submitted to the the WHO Expert Committee on Selection and Use of Essential Medicines. 6 Apr 2023.

- Comment on compulsory license for Paxlovid patent P2021-0232, filed by Pfizer on 6 August 2021. Evidence submitted to Oficina Nacional de la Propiedad Industrial (ONAPI), Dominican Republic. Available on request.
  
- [Risks posed by a US-UK trade agreement to NHS drug costs.](https://committees.parliament.uk/writtenevidence/12308/pdf/). Submitted to the EU Committee, International Agreements Sub-Committee, UK House of Lords. 23 Sept 2020.

- [Statement of the Lancet Youth Commission on Essential Medicines Policy (YCEMP).](https://web.archive.org/web/20220120153045/http://www.who.int/selection_medicines/committees/expert/20/reviews/open-session_YCEMP-statement_18-apr-15.pdf) Submission to the WHO 20th Expert Committee on the Selection and Use of Essential Medicines. 18 Apr 2015.

